Picard Reports Third Quarter 2025 Financial Results
Rhea-AI Summary
Picard Medical (NYSE: PMI) reported third-quarter 2025 results and corporate milestones on Nov 14, 2025. The company completed its IPO on Sept 2, 2025, raising approximately $19.5M gross ($15.5M net), and used proceeds to retire convertible debt and fund R&D and commercial expansion for SynCardia Total Artificial Heart.
Q3 revenue was $1.19M (+35% YoY); gross loss narrowed 81% to $0.13M; operating loss improved to $3.36M from $3.77M. Nine-month revenue was $3.93M (+11% YoY). Net loss was $22.7M, including a $12.4M non-cash derivative revaluation tied to convertible debt conversion. Picard also received a U.S. patent for its next‑generation implantable Total Artificial Heart and added two independent directors.
Positive
- IPO raised approximately $19.5M gross
- Q3 revenue of $1.19M (+35% YoY)
- Nine‑month revenue of $3.93M (+11% YoY)
- Issued U.S. Patent No. 12,383,722 B2 for implantable STAH
Negative
- Net loss of $22.7M for nine months
- Non‑cash derivative revaluation of $12.4M increased loss
- Cash used in operating activities $6.51M in Q3
- Derivative loss & interest of $6.94M in Q3
News Market Reaction
On the day this news was published, PMI gained 10.66%, reflecting a significant positive market reaction. Argus tracked a peak move of +9.8% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $19M to the company's valuation, bringing the market cap to $199M at that time.
Data tracked by StockTitan Argus on the day of publication.
– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence –
TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced financial results for the three and nine months ended September 30, 2025.
Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., commented, “The third quarter marked a pivotal moment for the company with the successful completion of its initial public offering in September. The IPO strengthened the balance sheet by retiring convertible debt, providing new capital to accelerate research, development, and commercial expansion across SynCardia’s life-saving artificial heart platform.”
Third Quarter and Recent Company Highlights
- IPO Completed: On September 2nd, Picard completed its IPO of common stock on the NYSE American (NYSE: PMI), raising approximately
$19.5 million in gross proceeds following full exercise of the underwriters’ over-allotment option. - Board Strengthened with Two Independent Appointments: On September 10th, Picard appointed independent directors Sam Van and George Ye to its Board of Directors. Mr. Van brings extensive capital-markets experience, while Mr. Ye adds deep leadership expertise in the global medical-device sector. Both appointments followed the Company’s initial public offering.
- Next-Generation “Emperor” Patent Granted: On September 22nd, Picard strengthened its intellectual-property portfolio with the issuance of U.S. Patent No. 12,383,722 B2, covering systems and methods for its next-generation fully implantable SynCardia Total Artificial Heart (the “Emperor”). The patent expands protection for advanced pump and control architectures designed to enhance patient mobility, building on prior U.S. Patents No. 11,918,798 B2 and No. 12,121,711 B2. The Company now holds 34 issued U.S. patent claims and China Patent No. 115279450 B, extending international protection.
Mr. Schnegelsberg added, “In the third quarter, we continued to secure additional patent protection, underscoring our commitment to the life-saving technology around our SynCardia Total Artificial Heart, or STAH, the most widely used and extensively studied artificial heart in the world. We also welcomed Sam Van and George Ye to our board; both of whom have deep leadership experience in complementary areas to advise the company in its next stage as a public company.”
Strong Third Quarter Driven by IPO Milestone and Revenue Growth
Picard Medical completed its initial public offering (IPO) on September 2, 2025, raising approximately
Revenue Growth and Improved Gross Margin
Third quarter revenue reached
Operating expenses were
Year-to-Date Performance for the Nine Months Ending September 30, 2025
For the nine-month period ending September 30, 2025, revenue totaled
| Jul-Sep | Jan-Sep | |||||||||||||
| Key Figures in Summary ('000) | 2025 | 2024 | Δ% | 2025 | 2024 | Δ% | ||||||||
| Revenue | 1,187 | 881 | 34.7 | % | 3,931 | 3,555 | 10.6 | % | ||||||
| Gross profit | (130 | ) | (673 | ) | -80.7 | % | (615 | ) | (248 | ) | 148.0 | % | ||
| Gross margin, % | -12 | % | -76 | % | -16 | % | -7 | % | ||||||
| EBITDA | (3,487 | ) | (4,444 | ) | -21.5 | % | (10,254 | ) | (10,140 | ) | 1.1 | % | ||
| EBITDA margin, % | -313 | % | -504 | % | -266 | % | -290 | % | ||||||
| Derivative Loss & Interest | (6,939 | ) | (1,762 | ) | 0.0 | % | - | - | 0.0 | % | ||||
| EBIT (Operating profit/loss) | (10,426 | ) | (6,206 | ) | -80.7 | % | (615 | ) | (248 | ) | 148.0 | % | ||
| EBIT margin, % | -12 | % | -76 | % | 0 | % | -16 | % | -7 | % | ||||
| Cash flows from Operating Activities | (6,514 | ) | (2,608 | ) | -149.8 | % | (11,296 | ) | (2,608 | ) | -333.1 | % | ||
| Earnings per share (EPS) | (0.19 | ) | (0.87 | ) | 77.9 | % | (0.96 | ) | (1.79 | ) | 46.6 | % | ||
| Sep-25 | Jun-25 | Sep-25 | Jun-25 | |||||||||||
| Debt paid at IPO | - | 8,248 | - | 8,248 | ||||||||||
| Debt converted into equity at IPO | - | 18,245 | - | 18,245 | ||||||||||
| Equity ratio, % | 59 | % | -291 | % | 59 | % | -291 | % | ||||||
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ
When did Picard Medical (PMI) complete its IPO and how much was raised?
What were Picard Medical (PMI) Q3 2025 revenue and operating loss figures?
How did Picard Medical (PMI) performance look year‑to‑date through Sept 30, 2025?
What caused the large non‑cash charge in Picard Medical (PMI) results?
Did Picard Medical (PMI) add corporate governance changes after the IPO?
What intellectual property update did Picard Medical (PMI) announce in Q3 2025?
